[{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"12f81b1d-451f-4a1e-b774-333646268edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009992","created_at":"2024-06-15T04:08:56.168Z","updated_at":"2024-07-02T16:34:26.237Z","phase":"Phase 2","brief_title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","source_id_and_acronym":"NCT05009992","lead_sponsor":"University of California, San Francisco","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-06-13"},{"id":"d7d5dd0d-e489-4e4c-a9c5-5f9b23ef89a2","acronym":"BIOMEDE 2","url":"https://clinicaltrials.gov/study/NCT05476939","created_at":"2022-07-27T13:54:43.500Z","updated_at":"2024-07-02T16:35:16.753Z","phase":"Phase 3","brief_title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0","source_id_and_acronym":"NCT05476939 - BIOMEDE 2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Modeyso (dordaviprone)"],"overall_status":"Recruiting","enrollment":" Enrollment 409","initiation":"Initiation: 09/29/2022","start_date":" 09/29/2022","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2024-03-01"},{"id":"fe9a8c97-4137-4e63-9045-01b237294fe6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04629209","created_at":"2021-01-19T20:36:09.384Z","updated_at":"2024-07-02T16:35:28.119Z","phase":"Phase 2","brief_title":"A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma","source_id_and_acronym":"NCT04629209","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-11-24"},{"id":"a103d7a1-1d6f-430c-8b15-91ec953041ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932643","created_at":"2021-01-18T19:22:14.463Z","updated_at":"2024-07-02T16:35:29.253Z","phase":"Phase 1","brief_title":"ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant","source_id_and_acronym":"NCT03932643","lead_sponsor":"University of Nebraska","biomarkers":" TP53 • RUNX1 • ASXL1","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation","tags":["TP53 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2023-11-14"},{"id":"985c92d2-fc43-4e40-b180-09c113e1c56e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03394027","created_at":"2021-01-18T16:44:56.063Z","updated_at":"2024-07-02T16:36:05.006Z","phase":"Phase 2","brief_title":"ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma","source_id_and_acronym":"NCT03394027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • EGFR positive • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • EGFR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 10/07/2021","study_completion_date":" 10/07/2021","last_update_posted":"2022-08-23"},{"id":"00fc36b5-fb5c-4743-870c-ddf1ebb39ac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04854044","created_at":"2021-04-22T21:53:11.171Z","updated_at":"2024-07-02T16:36:30.399Z","phase":"Phase 1b","brief_title":"ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma","source_id_and_acronym":"NCT04854044","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" SOX2 • NANOG","pipe":"","alterations":" ","tags":["SOX2 • NANOG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2021-05-12"}]